StreetInsider.com News Articles

OPTIMI Health adds 1mg and 2mg psilocybin doses for clinical research

Tue, 16 Jun 2026 08:33:03 -0400

Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) announced it has completed production of two microdose psilocybin finished drug products, formulated at 1mg and 2mg, available to qualified, authorized clinical research organizations.

The products are manufactured at the company's wholly owned GMP facility in Princeton, British Columbia, under a Health Canada Drug Establishment License. Optimi produces the products entirely in-house, from cultivating and harvesting mushrooms to generating a full-spectrum mushroom extract as the active pharmaceutical ingredient, through to encapsulation and packaging for export.

The two new formulations expand Optimi's existing psilocybin product range, which includes a 5mg capsule currently prescribed for

OPTIMI Health adds 1mg and 2mg psilocybin doses for clinical research

Tue, 16 Jun 2026 08:33:03 -0400

The two new formulations expand Optimi's existing psilocybin product range, which includes a 5mg capsule currently prescribed for

OPTIMI Health adds 1mg and 2mg psilocybin doses for clinical research

Tue, 16 Jun 2026 08:33:03 -0400

The two new formulations expand Optimi's existing psilocybin product range, which includes a 5mg capsule currently prescribed for

OPTIMI Health adds 1mg and 2mg psilocybin doses for clinical research

Tue, 16 Jun 2026 08:33:03 -0400

The two new formulations expand Optimi's existing psilocybin product range, which includes a 5mg capsule currently prescribed for

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Tue, 16 Jun 2026 08:30:00 -0400

Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies

New microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber Scheme

VANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, today announced it has completed production of two microdose psilocybin

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Tue, 16 Jun 2026 08:30:00 -0400

Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Tue, 16 Jun 2026 08:30:00 -0400

Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Tue, 16 Jun 2026 08:30:00 -0400

Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Tue, 16 Jun 2026 08:30:00 -0400

Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Tue, 16 Jun 2026 08:30:00 -0400

Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Tue, 16 Jun 2026 08:30:00 -0400

Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Tue, 16 Jun 2026 08:30:00 -0400

Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Tue, 16 Jun 2026 08:30:00 -0400

Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Tue, 16 Jun 2026 08:30:00 -0400

Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies

Optimi Health prices $15 million offering, lists on NASDAQ